Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.40 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CFB | P00751 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415416 | 0.90 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CCYP1A2CYP3A4 | |
| SCHEMBL4107387 | 0.89 | CFB (0.37) | ADRA2AADRA2BADRA2CCYP1A2CYP3A4 | |
| SCHEMBL2019626 | 0.87 | L3MBTL1 (0.49) | ADRA2AADRA2BADRA2CKCNN3KDM4E | |
| SCHEMBL1157281 | 0.85 | ADRA2A (0.32) | ADRA2AADRA2BADRA2CKCNN3KDM4E | |
| SCHEMBL3433520 | 0.84 | CFB (0.41) | ADRA2AADRA2BADRA2CCYP1A2CYP3A4 | |
| SCHEMBL3415101 | 0.84 | CFB (0.34) | ADRA2AADRA2BADRA2CCYP1A2CYP3A4 | |
| SCHEMBL1157463 | 0.84 | CFB (0.35) | ADRA2ACFBADRA1ATP53MAPT | |
| SCHEMBL3414421 | 0.82 | TAAR1 (0.42) | ADRA2AKDM4ENPSR1L3MBTL1CYP2D6 | |
| SCHEMBL1157481 | 0.81 | KCNA5 (0.36) | ADRA2AADRA2BADRA2CCYP1A2CYP3A4 | |
| SCHEMBL1157462 | 0.80 | KCNA5 (0.35) | ADRA2AADRA2BADRA2CCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102036664-B | Selective subtype alpha 2 adrenergic agents and methods of use thereof | ALLERGAN INC | 2012-11-28 | — | — | CN | disclosed |
| CN-102036664-A | Selective subtype alpha 2 adrenergic agents and methods of use thereof | ALLERGAN INC | 2011-04-27 | — | — | CN | disclosed |
| EP-2265269-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | Allergan, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009120648-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090239918-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239918-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | ADRA2A 3/4885ADRA2B 4/4885ADRA2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.